We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.
- Authors
Cesarini, Valeriana; Scopa, Chiara; Silvestris, Domenico Alessandro; Scafidi, Andrea; Petrera, Valerio; Del Baldo, Giada; Gallo, Angela
- Abstract
Glioblastoma (GBM) is the most aggressive, infiltrative, and lethal brain tumor in humans. Despite the extensive advancement in the knowledge about tumor progression and treatment over the last few years, the prognosis of GBM is still very poor due to the difficulty of targeting drugs or anticancer molecules to GBM cells. The major challenge in improving GBM treatment implicates the development of a targeted drug delivery system, capable of crossing the blood–brain barrier (BBB) and specifically targeting GBM cells. Aptamers possess many characteristics that make them ideal novel therapeutic agents for the treatment of GBM. They are short single-stranded nucleic acids (RNA or ssDNA) able to bind to a molecular target with high affinity and specificity. Several GBM-targeting aptamers have been developed for imaging, tumor cell isolation from biopsies, and drug/anticancer molecule delivery to the tumor cells. Due to their properties (low immunogenicity, long stability, and toxicity), a large number of aptamers have been selected against GBM biomarkers and tested in GBM cell lines, while only a few of them have also been tested in in vivo models of GBM. Herein, we specifically focus on aptamers tested in GBM in vivo models that can be considered as new diagnostic and/or therapeutic tools for GBM patients' treatment.
- Subjects
GLIOBLASTOMA multiforme; TARGETED drug delivery; BRAIN tumors; DRUG delivery systems; CELL separation; APTAMERS
- Publication
Molecules, 2020, Vol 25, Issue 18, p4267
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules25184267